Refine Search

Search Results -

Term	Documents
"E.COLI"	9451
E.COLIS	0
(23 AND "E.COLI").PGPB,USPT,USOC,EPAB,JPAB,DWPI.	0
(L23 AND E.COLI).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	0

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L24

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Monday, May 09, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L24	L23 and E.coli	0	L24
L23	L22 and @py<2000	7	L23
L22	L21 and L16	21	L22
L21	method same produce peptide	793	L21
L20	L19 and recombinant	7	L20
L19	L18 and @py<2000	9	L19
L18	L16 and E.coli	35	L18
L17	L16 and E.col	0	L17
L16	atrial natriuretic peptide	1365	L16
L15	L14 and L12	0	L15
L14	methods and recombinantion	43	L14

L13	L12 and L3	3	L13
L12	natriuretic peptides	1962	L12
L11	atric natriuretic peptides	0	L11
L10	L9 and @py<2000	13	L10
L9	L4 and L7	250	L9
L8	L7 and @py<2000	15	L8
L7	L3 and histidine	278	L7
L6	L4 and @py<2000	19	L6
L5	L4 and o-acetylserine	0	L5
L4	L3 and methionine	285	L4
L3	L2 and E.coli	385	L3
L2	L1 and recombination	5999	L2
L1	protein production	12084	L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1647

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS	17	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	18	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus

NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:02:36 ON 09 MAY 2005

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'CAPLUS' ENTERED AT 11:02:41 ON 09 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 9 May 2005  VOL 142 ISS 20
FILE LAST UPDATED: 8 May 2005  (20050508/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s method and produce and peptides
       2828419 METHOD
       1177967 METHODS
       3674782 METHOD
                 (METHOD OR METHODS)
        418006 PRODUCE
        159962 PRODUCES
        562114 PRODUCE
                 (PRODUCE OR PRODUCES)
        240498 PEPTIDES
L1        1421 METHOD AND PRODUCE AND PEPTIDES

=> s atrial natriuretic peptide
         23004 ATRIAL
             1 ATRIALS
         23004 ATRIAL
                 (ATRIAL OR ATRIALS)
         15717 NATRIURETIC
           404 NATRIURETICS
         15811 NATRIURETIC
                 (NATRIURETIC OR NATRIURETICS)
        328899 PEPTIDE
        240498 PEPTIDES
        421089 PEPTIDE
                 (PEPTIDE OR PEPTIDES)
L2        7216 ATRIAL NATRIURETIC PEPTIDE
                 (ATRIAL(W)NATRIURETIC(W)PEPTIDE)

=> s L1 and L2
L3           7 L1 AND L2

=> s L3 and E. coli
       1846798 E
        255790 COLI
```

```
          13 COLIS
      255799 COLI
                (COLI OR COLIS)
      109569 E. COLI
                (E(W)COLI)
L4         0 L3 AND E. COLI

=> sd L3 1-7, ibib,abs
SD IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

     (FILE 'HOME' ENTERED AT 11:02:36 ON 09 MAY 2005)

     FILE 'CAPLUS' ENTERED AT 11:02:41 ON 09 MAY 2005
L1         1421 S METHOD AND PRODUCE AND PEPTIDES
L2         7216 S ATRIAL NATRIURETIC PEPTIDE
L3            7 S L1 AND L2
L4            0 S L3 AND E. COLI

=> d L3 1-7 ibib,abs

L3   ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:740048  CAPLUS
DOCUMENT NUMBER:          141:237094
TITLE:                    Methods and compositions for measuring
                          biologically active and inactive natriuretic
                          peptides and for improving their therapeutic
                          potential
INVENTOR(S):              Buechler, Kenneth F.; Whittaker, Michael
PATENT ASSIGNEE(S):       Biosite Incorporated, USA
SOURCE:                   U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S.
                          Ser. No. 419,059.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   18
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2004176914         A1    20040909    US 2003-645874          20030820
     US 2003022235         A1    20030130    US 2001-835298          20010413
     US 2003109420         A1    20030612    US 2002-139086          20020504
     WO 2003016910         A1    20030227    WO 2002-US26604         20020820
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     US 2003219734         A1    20031127    US 2003-419059          20030417
     JP 2005049351         A2    20050224    JP 2004-238278          20040818
     WO 2005019819         A1    20050303    WO 2004-US26984         20040819
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
```

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-835298	A2	20010413
US 2001-288871P	P	20010504
US 2001-313775P	P	20010820
US 2001-315642P	P	20010828
US 2001-334964P	P	20011130
US 2002-346485P	P	20020102
US 2002-139086	A2	20020504
WO 2002-US26604	A2	20020820
US 2003-419059	A2	20030417
JP 2002-582250	A3	20020411
US 2003-645874	A	20030820
US 2004-542086P	P	20040204

AB The present invention describes compns. and **methods** designed to determine the presence or amount of biol. active natriuretic **peptides**, or their fragments, in a sample. The degradation of natriuretic **peptides** is an ongoing process that may be a function of, inter alia, the elapsed time between onset of an event triggering natriuretic peptide release into the tissues and the time the sample is obtained or analyzed; the quantity of proteolytic enzymes present; etc. This degradation can **produce** circulating amts. of natriuretic **peptides** having reduced or lost biol. function. The present invention provides, inter alia, assays designed to accurately measure biol. active natriuretic **peptides**, and compns. to inhibit a previously unknown pathway for degradation of natriuretic **peptides**.

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:405101 CAPLUS
DOCUMENT NUMBER: 137:308521
TITLE: Longstanding atrial fibrillation causes depletion of **atrial natriuretic peptide** in patients with advanced congestive heart failure
AUTHOR(S): van den Berg, Maarten P.; Tjeerdsma, Geert; Jan de Kam, Pieter; Boomsma, Frans; Crijns, Harry J. G. M.; van Veldhuisen, Dirk J.
CORPORATE SOURCE: Thorax Center, Department of Cardiology, University Hospital Groningen, Groningen, 9713 GZ, Neth.
SOURCE: European Journal of Heart Failure (2002), 4(3), 255-262
CODEN: EJHFFS; ISSN: 1388-9842
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Background: Congestive heart failure (CHF) is characterized by neurohormonal activation, including increased plasma concns. of **atrial natriuretic peptide** (ANP) and N-terminal ANP (N-ANP). Onset of atrial fibrillation (AF) further increases these **peptides**, but it may be hypothesized that concns. decrease during longstanding AF due to inherent atrial degeneration. Aim: We sought to investigate the relation between neurohormonal activation in patients with CHF and the duration of concomitant AF. **Methods**: The study group comprised 60 patients (age 70±8 yr) with advanced CHF due to left ventricular systolic dysfunction (left ventricular ejection fraction (LVEF) <0.35) and chronic AF (duration 21 (1-340) months). Plasma neurohormone concns. were measured, and multiple regression anal. was performed to identify their

clin. predictors. Results: Median plasma neurohormone concns. were: ANP 113 pmol/l, N-ANP 1187 pmol/l, norepinephrine 496 pg/mL, renin 127 μunits/l, aldosterone 128 pg/mL and endothelin 8.1 pg/mL. Norepinephrine, renin, aldosterone and endothelin were not significantly related to the duration of AF. In contrast, ANP decreased along with the duration of AF (P=0.03), while the same trend was observed for N-ANP (P=0.10). However, for these **peptides** a first order interaction with LVEF was present, which was not observed in the other neurohormones. In patients with LVEF >0.25 ANP and N-ANP increased along with the duration of AF, whereas in patients with LVEF≤0.25 an inverse relation between ANP (P=0.02) and N-ANP (P=0.04) and the duration of AF was present, longer-standing AF being associated with lower concns. Conclusion: In patients with advanced CHF with low LVEF plasma ANP and N-ANP concns. decrease during longstanding AF. This finding agrees with the concept that longstanding AF leads to impaired ability of the atria to **produce** these neurohormones due to inherent degenerative changes.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:131506 CAPLUS
DOCUMENT NUMBER: 136:199041
TITLE: Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and **methods** of culturing such cells
INVENTOR(S): Gorman, Cornelia M.; Groskreutz, Debyra J.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: U.S., 65 pp., Cont.-in-part of Appl. No. PCT/US92/10621.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6348327	B1	20020219	US 1993-26143	19930301
WO 9311247	A1	19930610	WO 1992-US10621	19921204
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1099758	A2	20010516	EP 2001-103965	19921204
EP 1099758	A3	20010523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
CA 2155434	AA	19940915	CA 1994-2155434	19940301
WO 9420624	A1	19940915	WO 1994-US2233	19940301
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 687301	A1	19951220	EP 1994-909843	19940301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08508398	T2	19960910	JP 1994-520124	19940301
US 2003031654	A1	20030213	US 2001-997868	20011128

PRIORITY APPLN. INFO.:

US 1991-803631	B2	19911206
US 1992-887265	B2	19920522
WO 1992-US10621	A2	19921204
EP 1993-900978	A3	19921204
US 1993-26143	A	19930301
WO 1994-US2233	W	19940301

AB Provided are animal host cells not naturally capable of forming secretory granules and that **produce** active, mature insulin by expression of a variant proinsulin containing a non-naturally occurring cleavage site and enzymic cleavage of the non-naturally occurring cleavage site in the host cells. Further provided are **methods** of culturing such cells.

REFERENCE COUNT: 175 THERE ARE 175 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:145197 CAPLUS
DOCUMENT NUMBER: 134:203411
TITLE: Recombinant secretory cells and their use in production of human insulin
INVENTOR(S): Newgard, Christopher B.; Halban, Philippe; Normington, Karl D.; Clark, Samuel A.; Thigpen, Anice E.; Quaade, Christian; Kruse, Fred
PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA; Betagene, Inc.
SOURCE: U.S., 109 pp., Cont.-in-part of U.S. Ser. No. 589,028. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6194176	B1	20010227	US 1997-785271	19970117
US 6087129	A	20000711	US 1996-589028	19960119
CA 2246268	AA	19970724	CA 1997-2246268	19970117
PRIORITY APPLN. INFO.:			US 1996-589028	A2 19960119

AB The present invention a provides **methods** for production of heterologous polypeptides, especially insulin, using a variety of recombinant secretory cell lines, such as neuroendocrine cells and insulinomas. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to **produce** the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are **methods** for engineering cells for high-level expression and **methods** for large-scale protein production Thus, stable expression of the human insulin gene in rat insulinoma cells that have had the endogenous insulin gene insertionally inactivated was demonstrated. These cells accurately processed the human proinsulin to insulin and secreted human insulin at the rate of 0.99 μg insulin/106 cells/h. The human cytomegalovirus immediate early promoter/enhancer and human growth hormone polyadenylation signals were used to control proinsulin gene expression.
REFERENCE COUNT: 236 THERE ARE 236 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:15390 CAPLUS
DOCUMENT NUMBER: 132:74527
TITLE: **Methods** for production of recombinant **peptides** with authentic amino termini
INVENTOR(S): Cottingham, Ian Robert; McKee, Colin Martin; Millar, Alan Robert
PATENT ASSIGNEE(S): PPL Therapeutics (Scotland) Limited, UK
SOURCE: PCT Int. Appl., 44 pp. CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000000625	A1	20000106	WO 1999-GB1907	19990616

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9943805	A1	20000117	AU 1999-43805		19990616
EP 1090132	A1	20010411	EP 1999-926622		19990616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
US 2002146779	A1	20021010	US 2000-746945		20001221
PRIORITY APPLN. INFO.:			GB 1998-13912	A	19980626
			US 1998-98281P	P	19980828
			WO 1999-GB1907	W	19990616

AB **Methods** for the production of **peptides** with authentic N-termini are provided. The **method** comprises expressing the peptide as part of a fusion protein wherein the peptide sequence incorporates a sequence extension at its N-terminus. The sequence extension may include an protease cleavage site. Alternatively, the sequence extension may include a modified intein, the self-splicing function of which has been disabled. The intein may be the yeast PI-Sce1 intein or a mini-intein from Mycobacterium tuberculosis recA. The fusion protein may addnl. comprise a label which allows for identification and/or purification of the fusion protein. Transgenic animals which **produce** the desired peptide in their milk are also disclosed..

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:214283 CAPLUS
DOCUMENT NUMBER: 128:280377
TITLE: **Method** for preparing radiolabeled **peptides** using protected polyaminocarboxylate ligands
INVENTOR(S): Srinivasan, Ananthachari
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5736120	A	19980407	US 1996-660262	19960607
PRIORITY APPLN. INFO.:			US 1996-660262	19960607

OTHER SOURCE(S): CASREACT 128:280377; MARPAT 128:280377

AB A **method** is provided for radiolabeling **peptides** using polyaminocarboxylate ligands having suitable protecting groups such that they can be added to **peptides** by standard solid phase or solution phase peptide synthetic chemical and can be deprotected using standard cleavage/deprotection reagents and **produce** the peptide/chelate conjugate as a high purity monoaddn. product is provided. The cleaved and deprotected ligand-peptide mols. can then be labeled with lanthanide or actinide radionuclides. The protected polyaminocarboxylate ligands form mono-anhydrides or mono-active esters under solid phase or solution phase conditions and permit only the desired monoaddn. chelate-peptide conjugate to be formed.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:499250 CAPLUS
DOCUMENT NUMBER: 127:172237
TITLE: Neuroendocrine cell lines for efficient synthesis and secretion of foreign proteins
INVENTOR(S): Newgard, Christopher B.; Halban, Philippe A.; Normington, Karl D.; Clark, Samuel A.; Thigpen, Anice E.; Quaade, Christian; Kruse, Fred; et al.
PATENT ASSIGNEE(S): Board of Regents, University of Texas System, USA; Betagene, Inc.; Newgard, Christopher B.; Halban, Philippe A.; Normington, Karl D.; Clark, Samuel A.; Thigpen, Anice E.
SOURCE: PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9726334	A1	19970724	WO 1997-US760	19970117
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6087129	A	20000711	US 1996-589028	19960119
CA 2246268	AA	19970724	CA 1997-2246268	19970117
AU 9718309	A1	19970811	AU 1997-18309	19970117
EP 876484	A1	19981111	EP 1997-903838	19970117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1996-589028 A2 19960119
WO 1997-US760 W 19970117

AB **Methods** of constructing neuroendocrine cell lines capable of high-level expression of a foreign gene and efficient secretion of the gene product are described. Such a cell line has lost the ability to express a gene that encodes a major cell gene product specific to the cell line. The host cell machinery normally used to **produce** this polypeptide then becomes spare production capacity for the synthesis of the foreign gene product. These lines or the gene products have a number of therapeutic uses, e.g. in treatment of disease, in the development of vaccines. The gene may be expressed from a strong animal or animal virus promoter and preferably it is an analog of the major gene inactivated in the development, e.g. a human gene expressed in an insulinoma-derived line. This makes use of the endogenous accessory systems for post-translational modification and secretion of the gene product. Stable expression of the human insulin gene in rat insulinoma cells that have had the endogenous insulin gene insertionally inactivated is demonstrated. These cells also efficiently secreted human insulin and accurately processed the human proinsulin to insulin.

=> d his

(FILE 'HOME' ENTERED AT 11:02:36 ON 09 MAY 2005)

FILE 'CAPLUS' ENTERED AT 11:02:41 ON 09 MAY 2005
L1 1421 S METHOD AND PRODUCE AND PEPTIDES

```
L2          7216 S ATRIAL NATRIURETIC PEPTIDE
L3             7 S L1 AND L2
L4             0 S L3 AND E. COLI

=> s Escherichia coli
        235369 ESCHERICHIA
             1 ESCHERICHIAS
        235370 ESCHERICHIA
                  (ESCHERICHIA OR ESCHERICHIAS)
        255790 COLI
            13 COLIS
        255799 COLI
                  (COLI OR COLIS)
L5      233445 ESCHERICHIA COLI
                  (ESCHERICHIA(W)COLI)

=> s L1 and L3 and L5
L6             1 L1 AND L3 AND L5

=> d L6

L6   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2000:15390  CAPLUS
DN   132:74527
TI   Methods for production of recombinant peptides with
     authentic amino termini
IN   Cottingham, Ian Robert; McKee, Colin Martin; Millar, Alan Robert
PA   PPL Therapeutics (Scotland) Limited, UK
SO   PCT Int. Appl., 44 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2000000625         A1    20000106    WO 1999-GB1907          19990616
         W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
             JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
             MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 9943805           A1    20000117    AU 1999-43805           19990616
     EP 1090132           A1    20010411    EP 1999-926622          19990616
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     US 2002146779        A1    20021010    US 2000-746945          20001221
PRAI GB 1998-13912        A     19980626
     US 1998-98281P       P     19980828
     WO 1999-GB1907       W     19990616
RE.CNT  12    THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1647

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 11:11:01 ON 09 MAY 2005
FILE 'CAPLUS' ENTERED AT 11:11:01 ON 09 MAY 2005
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      40.80      41.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -5.11      -5.11

=> file medline
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      40.80      41.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -5.11      -5.11

FILE 'MEDLINE' ENTERED AT 11:11:09 ON 09 MAY 2005

 FILE LAST UPDATED: 6 MAY 2005 (20050506/UP).  FILE COVERS 1950 TO DATE.

 On December 19, 2004, the 2005 MeSH terms were loaded.

 The MEDLINE reload for 2005 is now available.  For details enter HELP
 RLOAD at an arrow promt (=>).  See also:

    http://www.nlm.nih.gov/mesh/
    http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

 OLDMEDLINE now back to 1950.

 MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2005 vocabulary.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s methods and production and recombinant and peptides
       2200820 METHODS
        350577 PRODUCTION
          1812 PRODUCTIONS
        351348 PRODUCTION
                  (PRODUCTION OR PRODUCTIONS)
        239919 RECOMBINANT
          5553 RECOMBINANTS
        242807 RECOMBINANT
                  (RECOMBINANT OR RECOMBINANTS)
        180121 PEPTIDES
L7         216 METHODS AND PRODUCTION AND RECOMBINANT AND PEPTIDES
```

```
=> s atrial natriuretic peptide
         81784 ATRIAL
         18750 NATRIURETIC
            18 NATRIURETICS
         18759 NATRIURETIC
                 (NATRIURETIC OR NATRIURETICS)
        279999 PEPTIDE
        180121 PEPTIDES
        375755 PEPTIDE
                 (PEPTIDE OR PEPTIDES)
L8        7952 ATRIAL NATRIURETIC PEPTIDE
                 (ATRIAL(W)NATRIURETIC(W)PEPTIDE)

=> s L7 and L8
L9           0 L7 AND L8

=> s natriuretic peptide
         18750 NATRIURETIC
            18 NATRIURETICS
         18759 NATRIURETIC
                 (NATRIURETIC OR NATRIURETICS)
        279999 PEPTIDE
        180121 PEPTIDES
        375755 PEPTIDE
                 (PEPTIDE OR PEPTIDES)
L10      11030 NATRIURETIC PEPTIDE
                 (NATRIURETIC(W)PEPTIDE)

=> s Escherichia cili
        224164 ESCHERICHIA
             3 ESCHERICHIAS
        224164 ESCHERICHIA
                 (ESCHERICHIA OR ESCHERICHIAS)
            15 CILI
             1 CILIS
            16 CILI
                 (CILI OR CILIS)
L11          0 ESCHERICHIA CILI
                 (ESCHERICHIA(W)CILI)

=> s Escherichia coli
        224164 ESCHERICHIA
             3 ESCHERICHIAS
        224164 ESCHERICHIA
                 (ESCHERICHIA OR ESCHERICHIAS)
        240470 COLI
             5 COLIS
        240472 COLI
                 (COLI OR COLIS)
L12     223289 ESCHERICHIA COLI
                 (ESCHERICHIA(W)COLI)

=> d his

     (FILE 'HOME' ENTERED AT 11:02:36 ON 09 MAY 2005)

     FILE 'CAPLUS' ENTERED AT 11:02:41 ON 09 MAY 2005
L1          1421 S METHOD AND PRODUCE AND PEPTIDES
L2          7216 S ATRIAL NATRIURETIC PEPTIDE
L3             7 S L1 AND L2
L4             0 S L3 AND E. COLI
L5        233445 S ESCHERICHIA COLI
L6             1 S L1 AND L3 AND L5
```

```
     FILE 'MEDLINE' ENTERED AT 11:11:09 ON 09 MAY 2005
L7          216 S METHODS AND PRODUCTION AND RECOMBINANT AND PEPTIDES
L8         7952 S ATRIAL NATRIURETIC PEPTIDE
L9            0 S L7 AND L8
L10       11030 S NATRIURETIC PEPTIDE
L11           0 S ESCHERICHIA CILI
L12      223289 S ESCHERICHIA COLI

=> s L12 and L10 and L7
L13           0 L12 AND L10 AND L7

=> s L7 and L10
L14           0 L7 AND L10

=> s L7 and L10
L15           0 L7 AND L10

=> s L7 and L12
L16          62 L7 AND L12

=> s natriurectic
L17           1 NATRIURECTIC

=> s natriuretic peptide
          18750 NATRIURETIC
             18 NATRIURETICS
          18759 NATRIURETIC
                (NATRIURETIC OR NATRIURETICS)
         279999 PEPTIDE
         180121 PEPTIDES
         375755 PEPTIDE
                (PEPTIDE OR PEPTIDES)
L18       11030 NATRIURETIC PEPTIDE
                (NATRIURETIC(W)PEPTIDE)

=> d his

     (FILE 'HOME' ENTERED AT 11:02:36 ON 09 MAY 2005)

     FILE 'CAPLUS' ENTERED AT 11:02:41 ON 09 MAY 2005
L1          1421 S METHOD AND PRODUCE AND PEPTIDES
L2          7216 S ATRIAL NATRIURETIC PEPTIDE
L3             7 S L1 AND L2
L4             0 S L3 AND E. COLI
L5        233445 S ESCHERICHIA COLI
L6             1 S L1 AND L3 AND L5

     FILE 'MEDLINE' ENTERED AT 11:11:09 ON 09 MAY 2005
L7          216 S METHODS AND PRODUCTION AND RECOMBINANT AND PEPTIDES
L8         7952 S ATRIAL NATRIURETIC PEPTIDE
L9            0 S L7 AND L8
L10       11030 S NATRIURETIC PEPTIDE
L11           0 S ESCHERICHIA CILI
L12      223289 S ESCHERICHIA COLI
L13           0 S L12 AND L10 AND L7
L14           0 S L7 AND L10
L15           0 S L7 AND L10
L16          62 S L7 AND L12
L17           1 S NATRIURECTIC
L18       11030 S NATRIURETIC PEPTIDE

=> s L18 and L16
L19           0 L18 AND L16
```